The V-Go insulin treatment developed by Valeritas Inc. performed well in the latest study published in the official peer-reviewed journal of the American Association of Clinical Endocrinologists (AACE ...
BRIDGEWATER, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its ...
Zealand Pharma presents positive clinical and health economic outcome data with use of regular human insulin delivered by the V-Go in adults with type 2 diabetes Results of this 14-week randomized ...
The V-Go ® is a simple, fully disposable device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. The V-Go provides a continuous preset basal rate of insulin and allows ...
BRIDGEWATER, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers V-Go® Wearable Insulin Delivery device, a simple, all-in-one ...
* IN OLDER ADULTS WITH TYPE 2 DIABETES, USE OF HUMAN REGULAR INSULIN DELIVERED BY V-GO DEMONSTRATED SIMILAR GLYCEMIC CONTROL WITH NO INCREASED HYPOGLYCEMIA RISK COMPARED TO USE OF RAPID ACTING INSULIN ...
Zealand Pharma has found a buyer for its V-Go insulin delivery device. Weeks after lackluster sales led it to seek a partner for the device, Zealand has agreed to offload the technology and associated ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products ...
Copenhagen, April 15, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback